REGN Stock Analysis: Buy, Sell, or Hold?
REGN - Regeneron Pharmaceuticals Inc
$717.97
-1.91 (-0.27%)
▼
5d:
+1.25%
30d:
-4.77%
90d:
-8.38%
BUY
HIGH Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Smart Money Accumulation
REGN is down 4.4% this week, but smart money is accumulating calls. Top strike: $760 2026-06-18 with 253 OI. Call ratio: 82% View Scanner →
Strength: 5.4/10
Get Alerted When REGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: REGN trading at deep discount. Market pricing in -4.8% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: REGN trading at deep discount. Market pricing in -4.8% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1004.77
Based on 3.8% avg growth
INTRINSIC VALUE TODAY
$623.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: REGN is currently trading at $717.97, which is considered slightly low relative to its 30-day fair value range of $712.15 to $758.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.9) compared to its historical average (17.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, REGN is in a downtrend. The price is approaching resistance at $730.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $875.31 (+21.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, REGN is in a downtrend. The price is approaching resistance at $730.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $875.31 (+21.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$712.15 -
$758.92
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.6% below Wall St target ($875.31)
Trading Range Analysis
30-Day Trading Range
$712.15 -
$758.92
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$36.98
(5.2%)
Support & Resistance Levels
Support Level
$688.95
Resistance Level
$730.59
Current Trend
Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.94
Wall Street Target
$875.31
(+21.6%)
Revenue Growth (YoY)
19.0%
Earnings Growth (YoY)
-7.2%
Profit Margin
29.6%
Valuation Discount vs History
-4.8% cheaper
PE vs Historical
14.9 vs 17.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.8%
(market-implied from PE analysis)
1-Year Target
$685.33
(-5%)
2-Year Target
$652.43
(-9%)
3-Year Target
$621.11
(-14%)
3-Yr Target (if PE normalizes)
(PE: 15→17)
$719.44
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 3.6%)
$1182.82
(+64%)
Base:
(SPY PE: 14.9, Growth: 3.6%)
$801.55
(+11%)
Bear:
(PE: 12.7, Growth: 3.6%)
$681.31
(-5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 17.39 | Current EPS (TTM): $40.98
Bull Case
$922.16
(+28%)
Analyst growth 17.6%, PE expands to 19.1
Base Case
$838.33
(+17%)
Market implied 17.6%, PE stable at 17.4
Bear Case
$484.68
(-33%)
Severe decline -20.0%, PE contracts to 14.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.9 to 17.3
Stabilization Target:
$833.84
(+15.8%)
PE Expansion Potential:
+15.8%
Share & Embed Analysis
Last updated: May 14, 2026 11:31 AM ET
Data refreshes hourly during market hours. Next update: 12:31 PM
Data refreshes hourly during market hours. Next update: 12:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REGN showing a specific setup today?
Insider Activity (6 Months)
3
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Huda Y Zoghbi
SELL
1638 shares
2026-02-19
Julia Letlow
BUY
2026-02-12
Arthur F Ryan
SELL
100 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 67 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$118 | 57 HOLD |
Advanced REGN Option Strategies
Professional options setups generated by AI based on today's REGN price and gamma walls.
